TherapeuticsMD (TXMD) Provides Update on Third Quarter Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Oracle raises full year profit guidance, stock rises after hours
- Oil surges 6%, Brent and US crude both surpass $100 on more tanker attacks
- Analysts split on Apple after foldable iPhone Duo debut
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- White House copper tariff plan stalls amid affordability concerns, sources say
- Micron's Taiwan workers to get rewards worth up to 68 months of pay
- Crude Inventory 0.4M Barrels Last Week - EIA
- Vertiv shares drop on acquisition skepticism, AI pullback
- Copart nears $2B all-cash deal to acquire ACV Auctions - Bloomberg
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
TherapeuticsMD Provides Update on Third Quarter Progress
September 25, 2020 9:02 AM EDT-Company believes industry prescription tracking databases are not accurately tracking ANNOVERA®-
-Underlying retail and wholesale demand for ANNOVERA is strong and growing-
-Company experiencing record retail and wholesale growth for ANNOVERA-
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative womens healthcare company, today announced that the Company is on track to meet or exceed third quarter 2020 total net revenue consensus of $15.1 million. For the Companys ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system) product, the Company has seen... More
